RP-HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-03 and is reviewed periodically as new material appears.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The advanced heavy-water reactor is one of the few proposed large-scale uses of thorium. The IAEA's 2019 report lists about 846,500 tonnes of thorium in India's monazite deposits, based on 2010–2011 estimates. This total includes identified and undiscovered resources. The third and final core of the Shippingport Atomic Power Station 60 MWe reactor was a light water thorium breeder, which began operating in 1977. It used pellets made of thorium dioxide and uranium-233 oxide; initially, the U-233 content of the pellets was 5–6% in the seed region, 1.5–3% in the blanket region, and none in the reflector region. It operated at 236 MWt, generating 60 MWe, and ultimately produced over 2.1 billion kilowatt hours of electricity. After five years, the core was removed and found to contain nearly 1.4% more fissile material than when it was installed, demonstrating that breeding from thorium had occurred. A liquid fluoride thorium reactor is also planned as a thorium thermal breeder. Liquid-fluoride reactors may have attractive features, such as inherent safety, no need to manufacture fuel rods, and possibly simpler reprocessing of the liquid fuel. This concept was first investigated at the Oak Ridge National Laboratory Molten-Salt Reactor Experiment in the 1960s. From 2012 it became the subject of renewed interest worldwide.
=== In Singapore === On 3 August, Arcturus Therapeutics confirmed that the company had received approval for a clinical trial of ARCT-154 and another vaccine called ARCT-165 in Singapore. The Phase I-II clinical trial will evaluate the vaccines as a primary vaccination series and a booster following first dose with Pfizer–BioNTech COVID-19 vaccine. The study is being partially funded by a grant from the Singapore Government.
After his retreat, Liu established the "Ning-Ya-Kang Administrative Committee" in order to govern the areas still under his control. The Nationalist government would also follow suit in December 1934, creating a provincial establishment committee. Liu Wenhui was appointed by Nanjing as chairman of this committee: simultaneously, Liu Xiang was also named as the governor of Sichuan. It was officially formed in Ya'an in July 1935, and moved to Kangding in September 1936. Xikang was a poor region, isolated and rugged, and a reorganization by the Nationalists in 1936 would strip Liu of his rule over Ya'an and Xichang, which were turned over to Sichuan. The remaining lands were in such an impoverished state, with a population of barely 300,000 and a tax revenue of about 500,000 yuan, that Liu began to have trouble even securing food for the 24th Army. A desperate Liu Wenhui dispatched a mission to Nanjing to ask for his old territories back and for the central government to subsidize his budget; although Wang Jingwei was sympathetic to this idea, Chiang refused to grant him a bailout. Liu Xiang, the old rival of Liu Wenhui, likewise refused to return the regions he had just acquired, which stalled the plans to create an independent Xikang province. Respite for Liu would come in the form of the full-scale Japanese invasion of China, which forced the central government to move to Sichuan. More importantly, Liu Xiang would die from illness in 1938, clearing Sichuanese opposition to the Xikang project.
Sources: en.wikipedia.org
Hand therapy is often recommended. Approximately six weeks after surgery the patient is able completely to use the hand. The average recurrence rate is 39% after a fasciectomy after a median interval of about four years.
== Professional activities == Tippett's work in cybersecurity has led to roles as speaker, contributor and advisor to government and private sector organizations. From 2003 to 2005, he served on the President's Information Technology Committee (PITAC), established by Congress in 1997 under the High Performance Computing Act of 1991 to "guide the Administration's efforts to accelerate the development and adoption of information technologies vital for American prosperity in the 21st century." The U.S. Chamber of Commerce awarded Tippett its first Leadership in Health Care Award at the Chamber's first annual Health Care Summit (2012) for his leadership of Verizon's incubator. Tippett was also Chief Scientist for ICSA Labs and previously served as president of the International Computer Security Association. Tippett is currently an adjunct professor in the Division of General Medical Sciences at Case Western Reserve University School of Medicine. In November 2017, T.E.N., a technology and information security executive networking and relationship-marketing firm, announced that Tippett received the 2017 ISE® Luminary Leadership Award.
Ukrainian officials criticized the move. In January 2021, Sputnik Light commenced phase I/II trials. In February, Sputnik Light commenced phase III trials. Effectiveness is generally expected to slowly decrease over time. A real-world study with participants aged 60–79 years in Argentina found that the single-injection vaccine is 79% (95% CI, 75–82%) effective in preventing infections, 88% (95% CI, 80–92%) effective against hospitalization, and 85% (95% CI, 75–91%) against death. A phase III clinical trial in Russia also found an efficacy of 79%. According to Nextstrain, lineage B.1.1.317 was the dominant variant in Russia during the study period (5 December 2020 to 15 April 2021), while in Argentina (29 December 2020 to 21 March 2021) lineage N.5 dominated at first, but soon many lineages coexisted in similar proportions. Preliminary data from a study in Moscow in July 2021 indicate that the vaccine is 70% (95% CI, 64–75%) effective against symptomatic disease from the Delta variant for three months after vaccination. In August 2021, RDIF announced that preliminary results from a study on heterologous prime-boost vaccination indicate that it is safe to administer Sputnik Light as the first dose, then the Oxford–AstraZeneca, Moderna or Sinopharm BIBP vaccine as the second dose, as well as the homologous course consisting of Sputnik Light as the second dose. On 11 August 2021, the developers of the Sputnik V vaccine offered its 'Sputnik Light' (Ad26) vaccine to Pfizer for trial against the Delta variant.
It is the most popular type of soy sauce in Kyushu region of Japan, which is famous for sweet foods. In some cases, it is more common to find amakuchi shoyu than koikuchi shoyu in Kyushu. Newer varieties of Japanese soy sauce include:
Sources: en.wikipedia.org
Glyceollin synthase is an enzyme that catalyzes the last committed step in glyceollin biosynthesis. It has been classified as a cytochrome dependent monooxygenase. It cyclizes a prenyl residue in its starting materials to convert glyceollidins (I and II) into glyceollins (I - III). This enzyme catalyzes three chemical reactions, for example:
and B is the magnitude of the field. This means that the spin magnetization, which is proportional to the sum of the spin vectors of nuclei in magnetically equivalent sites (the expectation value of the spin vector in quantum mechanics), moves on a cone around the B field. This is analogous to the precessional motion of the axis of a tilted spinning top around the gravitational field. In quantum mechanics,
The first effect—the loss of AMP—is mostly significant because AMP contains ribose, a sugar molecule that is also used to make DNA, RNA, and some enzymes. Though the body can manufacture some ribose and obtain more from RNA-rich sources such as beans and red meat, this loss of ribose due to MADD is sometimes sufficient to create a shortage in the body, resulting in symptoms of severe fatigue and muscle pain. This outcome is especially likely if the individual regularly exercises vigorously or works physically over a period of weeks or months. The second effect, the absence of ammonia, is not well understood. It may result in a reduction of the amount of fumarate available to the citric acid cycle, and it may result in lower levels of nitric oxide (a vasodilator) in the body, reducing blood flow and oxygen intake during vigorous exercise, though this may be offset by increased levels of adenosine, another vasodilator. The third effect, the reduction in IMP, is also not well understood. It may somehow result in a reduction in the amount of lactic acid produced by the muscles, though serum lactate is typically slightly elevated with MADD. The following is a very simplified model of what may be going on inside a muscle cell with AMPD deficiency. There are two major semi-stable states: one with intra-cellular glycogen available, and one with glycogen exhausted. Both states are modified by how much the citric acid cycle is down-regulated by default. Start from the state where glycogen is available and the citric acid cycle is severely down-regulated.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.